Live Biotherapeutic Products And Microbiome CDMO Market Size, Top Share to 2033
The global live biotherapeutic products and microbiome CDMO market was valued at USD 55.19 million in 2024 and is projected to reach USD 1,075.98 million by 2033, growing at a CAGR of 39.10%. This growth is driven by increasing awareness of microbiome-based therapies, advancements in microbial engineering and AI-driven manufacturing, and supportive regulatory frameworks. North America currently dominates the market, while Asia-Pacific is expected to be the fastest-growing region.
Industrial Filtration Market Size, Share | Industry Report 2033
The global industrial filtration market is projected to reach USD 53.81 billion by 2033, growing at a CAGR of 4.6% from 2025 to 2033, driven by increasing industrial activity, stricter environmental regulations, and demand for cleaner air and water. North America currently dominates the market, with the U.S. leading the region, while Asia Pacific is expected to be the fastest-growing market. Key trends include the integration of smart technologies, a focus on sustainability, and customized filtration solutions, with liquid filtration holding the largest market share and air filtration anticipated to experience the fastest growth.
Top Clinical Trial Companies (CROs) Globally based on Q2 2025 Revenue
The global clinical trial services market was valued at USD 76.70 billion in 2024 and is projected to reach USD 132.05 billion by 2033, showing a CAGR of 6.3% from 2025-2033. The US leads in clinical trial activity, followed by China and India. Key players like Thermo Fisher Scientific (PPD Division), IQVIA, ICON plc, WuXi AppTec, Pharmaron, Charles River Laboratories, Fortrea, and Medpace demonstrated significant revenue in Q2 2025, buoyed by strong backlogs and increasing investor confidence in the sector.
Medtronic to cut 81 employees at California diabetes site
Medtronic (NYSE:MDT) is laying off 81 employees at its Northridge, California diabetes device facility, effective April 7, 2026. This restructuring comes as the company prepares to spin out its diabetes business, MiniMed, into a standalone public entity. The affected roles include engineering, IT, marketing, and technician positions, with Medtronic stating the cuts are necessary to ensure the new company's long-term success.
ICICI Prudential Asset Management Co Ltd Buys 6,000 Shares of Thermo Fisher Scientific Inc. $TMO
ICICI Prudential Asset Management Co Ltd increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 51.2% in the third quarter, purchasing an additional 6,000 shares to bring its total holding to 17,720 shares valued at $8.595 million. This makes Thermo Fisher Scientific the fund's 28th largest holding, representing 0.9% of its portfolio. The company recently reported better-than-expected earnings and authorized a $5.0 billion share buyback program.
China Universal Asset Management Co. Ltd. Invests $1.92 Million in Thermo Fisher Scientific Inc. $TMO
China Universal Asset Management Co. Ltd. recently acquired a new stake of 3,963 shares in Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $1.92 million during the third quarter. Despite significant insider selling over the last quarter, institutional investors maintain high ownership, and analysts largely rate the stock as a "Moderate Buy" with a consensus price target of $633.68. The company also recently authorized a $5.0 billion share buyback program after beating quarterly EPS and revenue estimates.
Factory Mutual Insurance Co. Increases Holdings in Thermo Fisher Scientific Inc. $TMO
Factory Mutual Insurance Co. has increased its stake in Thermo Fisher Scientific Inc. by 2.6%, bringing its total holdings to 98,935 shares valued at $47.985 million. Other institutional investors also raised their positions, with institutional ownership of Thermo Fisher now standing at 89.23%. The company recently exceeded quarterly earnings and revenue expectations and announced a $5 billion share repurchase program, despite some insider selling.
CenterBook Partners LP Raises Stock Position in Thermo Fisher Scientific Inc. $TMO
CenterBook Partners LP significantly increased its stake in Thermo Fisher Scientific Inc. (TMO) by 311.6% in the third quarter, now owning 3,791 shares valued at $1.84 million. Other institutional investors also adjusted their positions in the medical research company. The article also details recent insider stock sales, analyst price targets, and Thermo Fisher Scientific's recent financial performance, including its earnings beat and a $5 billion share repurchase plan.
Fiera Capital Corp Has $73.42 Million Holdings in Thermo Fisher Scientific Inc. $TMO
Fiera Capital Corp reduced its stake in Thermo Fisher Scientific Inc. by 3.1% in the third quarter, now holding 151,374 shares valued at $73.42 million. Despite this, Thermo Fisher Scientific reported strong quarterly earnings, surpassing analyst expectations, and announced a $5.00 billion share repurchase program. Analysts maintain a "Moderate Buy" rating for the stock with an average price target of $633.68, even as company insiders have sold a significant number of shares recently.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The fill finish manufacturing market is projected to grow from $11.96 billion in 2025 to $21.04 billion by 2030, driven by the increasing demand for advanced therapies, personalized medicine, and outsourcing to CMOs. Key trends include the adoption of automated lines, aseptic processing, and single-use consumables. North America currently holds the largest market share, with Asia-Pacific expected to be the fastest-growing region.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The fill-finish manufacturing market is experiencing significant growth, projected to reach over $21 billion by 2030, driven by increased demand for biopharmaceuticals, cell and gene therapies, and personalized medicine. Key market drivers include advancements in aseptic filling technologies, rising outsourcing to CMOs, and a stronger focus on regulatory compliance. Major players like Johnson & Johnson, AbbVie, and Thermo Fisher Scientific are leading the innovation in this sector, with Asia-Pacific expected to be the fastest-growing region.
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
The global fill-finish manufacturing market is projected to grow from $11.96 billion in 2025 to over $21 billion by 2030, driven by surge in demand for cell and gene therapies and biologics. Key industry trends include the adoption of automated fill-finish lines, aseptic processing solutions, and increased outsourcing to contract manufacturing organizations (CMOs).
2,910 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by First National Bank of Omaha
First National Bank of Omaha recently acquired 2,910 shares of Thermo Fisher Scientific Inc. (TMO) worth approximately $1.41 million. This investment comes despite significant insider selling activities totalling over $63 million in the past 90 days. The company's board has also authorized a $5.0 billion share repurchase program and reported strong quarterly earnings, beating analyst expectations.
ClearBridge Appreciation ESG Strategy adds new stake in Arista Networks in Q4, exits Oracle
The ClearBridge Appreciation ESG Strategy initiated a new position in Arista Networks during the fourth quarter while divesting its stake in Oracle. The strategy also increased its holdings in companies like Salesforce and Microsoft, reflecting a focus on software-as-a-service growth and AI beneficiaries, respectively. Conversely, positions in Fiserv and Thermo Fisher Scientific were reduced.
A Look At Avantor (AVTR) Valuation After A Year Of Weak Shareholder Returns
Avantor (AVTR) has experienced a significant share price decline over the past year, resulting in a negative shareholder return and a low value score. Despite this, a common narrative suggests the stock is undervalued by about 43% with a fair value of $13.04, driven by growth in biologics and personalized medicine. However, potential risks like weaker bioprocessing demand and elevated leverage could challenge this undervalued thesis, prompting investors to conduct their own analysis.
Here’s Why Thermo Fisher Scientific (TMO) Traded Lower in Q2
The article discusses the reasons behind Thermo Fisher Scientific's (TMO) stock underperformance in Q2, primarily attributing it to declining COVID-19 testing revenue and a decrease in demand for bioproduction and pharma services. Despite these headwinds, the company's core business remains strong, showing consistent growth. The analysis also covers TMO's valuation, insider trading activity, and ongoing share repurchase program.
Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative
Charles River Laboratories International (CRL) recently reported its FY 2025 third-quarter numbers, showing a revenue of US$1,004.9 million and EPS of US$1.11, moving away from a previous net loss. The company has posted three consecutive quarters of positive net income in FY 2025, contrasting with a trailing 12-month net loss of US$83.5 million. While analysts expect continued growth and a return to profitability over the next three years, skeptics note that the trailing 12-month EPS remains a loss and historical losses have widened, suggesting the recovery is still in its early stages.
Ontario Teachers Pension Plan Board Purchases New Stake in Thermo Fisher Scientific Inc. $TMO
The Ontario Teachers Pension Plan Board has acquired a new stake of 23,798 shares in Thermo Fisher Scientific Inc. (NYSE:TMO), valued at approximately $11.54 million, during the third quarter. The company recently reported strong quarterly earnings, beating analyst estimates with $6.57 EPS and $12.22 billion in revenue, and its board approved a $5.00 billion share buyback program. Analyst sentiment for Thermo Fisher Scientific is generally positive, with a "Moderate Buy" consensus rating and an average price target of $633.68.
King Luther Capital Management Corp Has $329.87 Million Holdings in Thermo Fisher Scientific Inc. $TMO
King Luther Capital Management Corp decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.3% during the third quarter, reducing its holdings to 680,119 shares valued at approximately $329.87 million. The article also details other institutional investor activity, significant insider stock sales by EVP Michael D. Shafer and COO Michel Lagarde, and recent analyst ratings. Thermo Fisher Scientific reported strong quarterly earnings, beating analyst estimates, and has initiated a $5.00 billion share repurchase program.
RNAi Therapeutics Market to hit US$ 8.80 Billion by 2033 | North
The global RNAi Therapeutics Market is projected to reach US$ 8.80 billion by 2033, growing from US$ 2.60 billion in 2024 at a CAGR of 14.6%. North America currently leads the market with a 40% share, driven by key biotech companies and high R&D investments. The market growth is fueled by advancements in gene-silencing technologies, product innovations, and strategic acquisitions, with a focus on treating rare and chronic conditions.
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its critical role in drug development, personalized medicine, and biotech research. Key technologies include X-ray crystallography, NMR, and cryo-EM, with North America currently dominating and Asia-Pacific showing rapid growth due to increased R&D and AI integration. Challenges like high equipment costs and a shortage of skilled personnel persist, but technological advancements and strategic investments are propelling market expansion.
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its crucial role in drug development, personalized medicine, and biotech research. Key technologies like X-ray crystallography, NMR, and cryo-EM are central to this growth, with North America currently dominating and Asia-Pacific showing rapid expansion. The market faces challenges such as high equipment costs and a shortage of skilled personnel, but technological advancements and strategic investments are propelling its forward trajectory.
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More
The global market for cell and gene therapy tools and reagents is projected to reach $19.8 billion by 2030, growing at a CAGR of 10.6% from $12 billion in 2025. This growth is driven by increasing clinical and commercial activities in cell and gene therapies (CGTs), significant R&D investments, and regulatory approvals for novel CGTs. The market report provides comprehensive insights into segmentation by product type, application, and end-user, profiling key players such as Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, and Sartorius.
United States Cancer Biomarker Market is Going to Boom | Merck KGaA • QIAGEN • Illumina • Myriad Genetics
Coherent Market Insights has released a comprehensive report on the United States Cancer Biomarker Market, forecasting its growth from 2026-2033. The report analyzes market trends, competition, geographic distribution, and identifies key players such as Roche, Thermo Fisher Scientific, and Illumina. It also outlines market segmentation for diagnostics, prognostics, therapeutics, and personalized medicine, providing insights for stakeholders.
Liquid Handling System Market Is Going to Boom | Thermo Fisher Scientific • Eppendorf AG • Sartorius AG • Gilson Inc
A new report by Coherent Market Insights projects significant growth for the Liquid Handling System Market between 2026 and 2033, driven by various factors including increased demand and technological advancements. The comprehensive analysis covers market size, trends, competitive landscape, regional insights, and future growth opportunities. Key players identified include Thermo Fisher Scientific, Eppendorf AG, Sartorius AG, and Gilson Inc.
Thermo Fisher Launches Kit for Sequential Protein, DNA and RNA Extraction
Thermo Fisher Scientific has introduced a new Sequential Protein/DNA/RNA Extraction Kit designed to extract all three biomolecules from a single biological sample. This innovation aims to help researchers maximize the utility of scarce tissue and cell materials, particularly in cancer and disease studies. The kit facilitates integrated proteomic and genomic analysis from the same specimen, streamlining workflows and supporting deeper insights into disease mechanisms.
Can Thermo Fisher Scientific Stock Recover If Markets Fall?
Thermo Fisher Scientific (TMO) stock has recently fallen by 17.0% due to concerns about its 2026 outlook and a biotech funding slowdown. The article analyzes the stock's resilience during past economic downturns, including the 2022 Inflation Shock, 2020 Covid Pandemic, 2018 Correction, and 2008 Global Financial Crisis, comparing its performance and recovery time against the S&P 500. It concludes that TMO currently shows weak operational performance and high valuation, making it unattractive, but historically has often been more resilient than the broader market in downturns.
Is Revvity (RVTY) Now Offering Value After Recent Share Price Weakness
Revvity (RVTY) has experienced recent share price weakness, with declines over the past week, month, and year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 29.0% at its current price of US$97.74, with an estimated intrinsic value of $137.75 per share. However, its current P/E ratio of 46.19x is higher than Simply Wall St's proprietary "Fair Ratio" of 24.83x, indicating it might be overvalued by that metric.
Michael Hakes' Top Picks: Nu Holdings, Thermo Fisher Scientific & Amazon.com
Michael Hakes, a senior portfolio manager at Murray Wealth Group, has revealed his top stock selections for investors to consider. His chosen picks include Nu Holdings, Thermo Fisher Scientific, and Amazon.com. This article highlights these companies as key stocks to watch in the current market.
Thermo Fisher boosts connected planning with Oracle Cloud EPM
Thermo Fisher Scientific, a global leader in life sciences, has adopted Oracle Fusion Cloud Enterprise Performance Management (EPM) to enhance its enterprisewide planning. This move aims to address challenges stemming from significant growth, including managing diverse teams, supporting a large global sales channel, and overcoming data management issues from disparate systems. By centralizing data and improving collaboration with Oracle Cloud EPM, Thermo Fisher seeks to boost productivity, enable more strategic planning, and support its 3,000 finance and accounting users more effectively.
DNA RNA Banking Services Market Is Going to Boom | Thermo Fisher Scientific • Illumina • 23andMe • AncestryDNA
This report by Coherent Market Insights analyzes the DNA RNA Banking Services Market, predicting substantial growth from 2026 to 2033 due to rising demand and innovation. It covers key market trends, drivers, competitive landscape, and strategic opportunities for industry leaders, identifying major players like Thermo Fisher Scientific and Illumina. The study utilizes analytical tools like SWOT analysis and Porter's Five Forces to provide comprehensive insights and forecasts for various segments and regions.
Life Science Precision Parts Research Report 2025: A $13.92 Billion Market by 2030 Featuring Key Players - Gemsons, Arc, Precision Resource, Thermo Fisher Scientific, Stryker, Linamar, TS Prototypes
The global Life Science Precision Parts market is projected to grow from $9.50 billion in 2024 to $13.92 billion by 2030, driven by automation in laboratory and biotech research, and increasing demand for diagnostic devices. North America currently leads the market due to its advanced healthcare infrastructure and regulatory standards, while injection molded components dominate the product type due to their cost-effectiveness and precision. Key players include Gemsons, Arc Group Worldwide, Precision Resource, Thermo Fisher Scientific, Stryker Corporation, Linamar Corporation, and TS Prototypes.
AdaptHealth Corp. (AHCO) Stock Analysis: Healthcare Giant Set For Potential 31% Upside
AdaptHealth Corp. (AHCO), a significant player in home medical equipment, is poised for potential growth, with analysts projecting a 31% upside from its current trading price of $10.20. The company shows reasonable future earnings with a forward P/E of 10.26 and strong operational efficiency, generating $191.7 million in free cash flow, despite some missing traditional valuation metrics. AdaptHealth's comprehensive product suite and strategic alignment with major healthcare payors position it well for sustained growth in the expanding home healthcare market.
Gas Chromatography Systems Market to Reach US$7.20 Billion
The global Gas Chromatography Systems Market is projected to reach US$7.20 billion by 2032, growing at an 8.8% CAGR from 2025 to 2032, up from US$3,668.75 million in 2024. This growth is driven by increasing demand for advanced analytical instrumentation in various sectors like environmental analysis, pharmaceuticals, and food safety, with North America leading the market. Key players like Thermo Fisher Scientific, Agilent Technologies, and Shimadzu Corporation are advancing the market through technological innovations in detector sensitivity, automation, AI integration, and the development of portable systems.
QXO, Apollo Global, Thermo Fisher Scientific And More On CNBC's 'Final Trades'
This article highlights several "Final Trades" discussed on CNBC, featuring QXO, Apollo Global Management, Thermo Fisher Scientific, and the iShares US Consumer Discretionary ETF. Analysts offer their picks based on recent company news, earnings reports, and market performance. QXO's recent acquisition, Apollo Global's strong quarterly results, and Thermo Fisher Scientific's better-than-expected earnings were some of the driving factors behind the selections.
Thermo Fisher Scientific Inc. $TMO Stake Boosted by NEOS Investment Management LLC
NEOS Investment Management LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.6% in the third quarter, bringing their total holdings to 51,364 shares valued at $24.91 million. Other institutional investors also adjusted their positions, and 89.23% of the company's stock is owned by institutional investors and hedge funds. The company recently posted strong earnings, beating analyst estimates, and announced a $5.00 billion share buyback plan.
Mondrian Investment Partners LTD Purchases Shares of 304,345 Thermo Fisher Scientific Inc. $TMO
Mondrian Investment Partners LTD has acquired a new position of 304,345 shares in Thermo Fisher Scientific (NYSE:TMO) during the third quarter, valued at approximately $147.6 million, making it their 12th-largest holding. This comes as Thermo Fisher Scientific recently surpassed earnings estimates and authorized a $5.0 billion share repurchase program. Analysts currently have a consensus price target of $633.68, significantly higher than its current trading level of around $505.
Shell Asset Management Co. Has $742,000 Stock Position in Thermo Fisher Scientific Inc. $TMO
Shell Asset Management Co. significantly reduced its stake in Thermo Fisher Scientific Inc. by 93.2% in the third quarter, bringing its total holdings to $742,000. Despite this sell-off, Thermo Fisher Scientific surpassed quarterly earnings and revenue estimates and announced a $5.00 billion share buyback program. The company maintains a "Moderate Buy" consensus rating from analysts with a target price of $633.68.
HighTower Advisors LLC Buys 2,143 Shares of Thermo Fisher Scientific Inc. $TMO
HighTower Advisors LLC increased its stake in Thermo Fisher Scientific Inc. by 1.5% in the third quarter, purchasing an additional 2,143 shares and bringing their total holdings to 146,255 shares valued at $70.94 million. Other institutional investors like Vanguard Group Inc., Norges Bank, Franklin Resources Inc., Bank of New York Mellon Corp, and Charles Schwab Investment Management Inc. also significantly modified their positions in the medical research company. Analysts have issued a "Moderate Buy" consensus rating for TMO with a target price of $633.68, while some insiders have recently sold shares.
Crestwood Advisors Group LLC Purchases 4,484 Shares of Thermo Fisher Scientific Inc. $TMO
Crestwood Advisors Group LLC increased its stake in Thermo Fisher Scientific Inc. by 4.7% in the third quarter, adding 4,484 shares to own a total of 99,793 shares valued at $48.4 million. The company recently reported strong quarterly earnings, beating expectations with an EPS of $6.57 and revenue of $12.22 billion, and approved a $5.0 billion share repurchase plan. Analyst sentiment for Thermo Fisher Scientific is largely bullish, with an average "Moderate Buy" rating and a target price of $633.68.
Gene Editing Market: Exploring Future Business Opportunities
This press release from Coherent Market Insights details a research report on the Gene Editing Market, forecasting substantial growth from 2026 to 2033. The report analyzes key market trends, drivers, challenges, and competitive landscapes, featuring major players like CRISPR Therapeutics and Editas Medicine. It provides insights into market segmentation, geographical landscapes, and future opportunities to aid businesses in strategic decision-making.
Molecular Diagnostics Market is expected to reach US$ 37.19 billion by 2033 | Major key players - Hologic Inc, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, QIAGEN N.V
The global Molecular Diagnostics Market is projected to reach US$ 37.19 billion by 2033, growing at a CAGR of 5.8% from US$ 21.01 billion in 2024. Key market players include Hologic Inc, F. Hoffmann-La Roche Ltd, and Thermo Fisher Scientific Inc. Recent developments in the US and Japan highlight advancements in cancer detection, infectious disease testing, and personalized medicine, driven by new technologies and regulatory approvals.
$11.88 Bn Semiconductor Cleanroom Markets - Global Forecast to 2030 with Daifuku, MURATA MACHINERY, Exyte Group, DuPont, and Thermo Fisher Scientific Leading
The global semiconductor cleanroom market is projected to reach USD 11.88 billion by 2030, growing at an 8.0% CAGR from 2025, driven by the increasing need for advanced contamination control in semiconductor manufacturing. The cleanroom infrastructure & systems segment was the largest in 2024, while fan filter units are expected to see the fastest growth. India is anticipated to lead regional growth due to its expanding semiconductor ecosystem.
$11.88 Bn Semiconductor Cleanroom Markets - Global Forecast
The global semiconductor cleanroom market is expected to reach USD 11.88 billion by 2030, growing at an 8.0% CAGR from 2025. This growth is primarily driven by the increasing need for advanced contamination control in semiconductor manufacturing, particularly with shrinking device geometries and processes like EUV lithography and 3D NAND. India is projected to exhibit the highest CAGR due to its expanding semiconductor ecosystem and government initiatives.
Zions Bancorporation National Association UT Boosts Stock Holdings in Thermo Fisher Scientific Inc. $TMO
Zions Bancorporation National Association UT significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.5% in the third quarter, bringing its total holdings to 12,639 shares valued at $6.13 million. This move is part of a broader trend of institutional investment, with other major funds like Vanguard Group, Norges Bank, Franklin Resources, Bank of New York Mellon Corp, and Charles Schwab Investment Management also adjusting their positions. Despite recent insider selling, analysts maintain a "Moderate Buy" consensus rating for TMO with a target price of $633.68, reflecting confidence in the company's financial performance and a recent $5 billion stock buyback authorization.
Vanguard Group Inc. Has $16.42 Billion Holdings in Thermo Fisher Scientific Inc. $TMO
Vanguard Group Inc. significantly increased its stake in Thermo Fisher Scientific Inc., owning 9.01% of the company, valued at approximately $16.42 billion. Thermo Fisher Scientific recently surpassed quarterly earnings and revenue estimates and authorized a $5.0 billion share buyback program. The company maintains a "Moderate Buy" consensus rating from analysts, with several firms raising their price targets, despite recent insider stock sales.
M&G PLC Buys 47,644 Shares of Thermo Fisher Scientific Inc. $TMO
M&G PLC increased its stake in Thermo Fisher Scientific Inc. by 12.1%, purchasing 47,644 additional shares to hold a total of 441,410 shares, making it their 28th-largest holding. Despite significant insider selling over the past 90 days, the company reported strong quarterly earnings, beating EPS and revenue estimates, and authorized a $5 billion share buyback. Analysts maintain a "Moderate Buy" consensus rating with a price target of $633.68 for Thermo Fisher Scientific.
Eagle Rock Investment Company LLC Buys 8,246 Shares of Thermo Fisher Scientific Inc. $TMO
Eagle Rock Investment Company LLC significantly increased its stake in Thermo Fisher Scientific (NYSE:TMO) by 77.0% in Q3, purchasing 8,246 shares to hold a total of 18,957 shares valued at $9.20 million. Thermo Fisher Scientific demonstrated strong financial performance, beating quarterly earnings and revenue estimates and announcing a $5.0 billion share repurchase program. Analysts maintain a "Moderate Buy" consensus rating for TMO, with an average target price of $633.68, reflecting continued confidence in the medical research company.
Fifth Third Bancorp Has $158.92 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO
Fifth Third Bancorp recently increased its stake in Thermo Fisher Scientific Inc. (TMO) by 2.0%, now holding 327,665 shares valued at approximately $158.92 million. Despite this, several insiders have sold significant amounts of stock. Thermo Fisher Scientific reported strong quarterly earnings, beating estimates, and announced a $5.0 billion share repurchase program, with analysts maintaining a "Moderate Buy" rating.
Assetmark Inc. Has $14.86 Million Stock Position in Thermo Fisher Scientific Inc. $TMO
Assetmark Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.9% in the third quarter, bringing its holding to 30,631 shares valued at $14.86 million. The company has a "Moderate Buy" consensus rating from analysts with an average target price of $633.68, and institutional ownership stands at 89.23%. Thermo Fisher Scientific recently exceeded quarterly EPS and revenue estimates and authorized a $5 billion share buyback program.
